At the end of its evaluation, the HAS considers that the PCV 20 vaccine can be integrated into the French vaccination strategy for the prevention of invasive diseases and pneumococcal pneumonia in people at risk aged 18 and over.

HAS considers that the additional benefits conferred by the addition of seven serotypes as well as a simplification of the vaccination schedule justify the preferential use of the PCV 20 vaccine alone to replace the PCV 13 – VPP 23 schedule currently in force. The HAS therefore no longer recommends the use of the PCV 13 and VPP 23 vaccines in adults.

  • Recommendation
  • Europe
  • France
  • Pneumococcal disease